The US Food and Drug Administration on Wednesday approved Pfizer’s RSV vaccine for older adults, the second such shot approved for the common virus. Earlier in May, the agency approved the world ...

Moderna filed for FDA approval on data from a late-stage trial that showed its vaccine was 83.7% effective at preventing at least two symptoms of RSV, such as cough and fever.

The Food and Drug Administration on Wednesday approved Pfizer’s vaccine against the respiratory syncytial virus, or R.S.V., for adults age 60 and older, the second approval granted for shots ...

Vaccinating adults in their 50s for RSV likely has a public health benefit, a work group within the CDC's committee concluded last year ahead of the approval, though it is narrower than for older ...

FDA approves world's first RSV vaccine, a shot for adults ages 60 and up GSK's single-dose shot lowered the risk of severe illness by 94% in older adults. May 3, 2023, 1:12 PM EDT / Updated May 3 ...

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the ...

US FDA approves Pfizer’s RSV vaccine Abrysvo for adults aged 18 to 59 at increased risk for disease. Pfizer Inc. News release. October 22, 2024. Accessed October 23, 2024.

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

US regulators approved Moderna Inc.’s vaccine to prevent a common respiratory illness for more adults, a potential easing of the Trump administration’s opposition to mRNA technology.

RSV typically causes cold-like symptoms, but is also a leading cause of pneumonia in toddlers and older adults. The CDC estimates 15,000–20,000 annual RSV-associated hospitalizations in the U.S ...

FDA approves Novavax's COVID-19 vaccine with limitations. ... The FDA granted Pfizer-BioNTech full approval for those 12 and older in August 2021 and Moderna in January 2022.